amylin glp-1 dual agonist Amycretin — a novel obesity treatment that targets both and receptors — has shown early success in phase 1 testing and will be advanced into phase 3 testing. http://ms.spr.ly/6185SLoJD 📢 Beyond GLP-1: The next

Because BPC-157, copper peptides, and melanocortin derived fragments differ in size and binding behavior, studies may use them together to probe compatibility, stability, and assay specific performance under controlled laboratory conditions

these are moisturising creams gifted to her and gels she posted about as a favour, to promote their launch

Also, the test duration is only 90 minutes, with only 4 sample collections required, compared with 2 hours for the ITT and 4 hours for the GST

Early trials suggest it may be effective not just on its own, but especially when combined with GLP-1 therapies, creating a powerful one-two punch against overeating and excess weight